CEL-SCI Corp
$ 1.20
1.69%
28 Jul - close price
- Market Cap 20,623,000 USD
- Current Price $ 1.20
- High / Low $ 1.22 / 1.16
- Stock P/E N/A
- Book Value 0.81
- EPS -2.15
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.70 %
- ROE -3.05 %
- 52 Week High 13.48
- 52 Week Low 0.89
About
CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia.
Analyst Target Price
$15.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-12 | 2025-12-23 | 2025-08-14 | 2025-05-14 | 2025-01-13 | 2024-12-31 | 2024-08-14 | 2024-05-16 | 2024-02-14 | 2023-12-22 | 2023-08-11 | 2023-05-12 |
| Reported EPS | -0.68 | -0.86 | -1.36 | -2.3323 | -2.7 | -2.7003 | -4.2 | -8.4 | -4.2 | -0.16 | -5.7 | -5.7 |
| Estimated EPS | 0 | None | None | None | -3.3 | -0.1 | -3.9 | -4.2 | -4.2 | -0.16 | -4.5 | -5.1 |
| Surprise | -0.68 | 0 | 0 | 0 | 0.6 | -2.6003 | -0.3 | -4.2 | 0 | 0 | -1.2 | -0.6 |
| Surprise Percentage | None% | None% | None% | None% | 18.1818% | -2600.3% | -7.6923% | -100% | 0% | 0% | -26.6667% | -11.7647% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVM
2026-07-28 04:12:16
This article provides a technical analysis of CEL-SCI Corp (CVM), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 4.87 and is trading within a range of $0.99 to $1.42. Based on the analysis, a neutral signal is indicated, with specific indicators showing both sell signals and neutral positions.
2026-07-27 20:40:05
This article provides a comprehensive stock analysis of CEL-SCI Corp (CVM) through TradingKey's stock score, highlighting its relatively healthy fundamentals and high growth potential. Despite being fairly valued within its industry, having high institutional ownership, and recent "Buy" ratings from analysts, the stock is expected to trend down in the medium term due to weak fundamentals and technicals. The company, a late clinical-stage biotechnology firm, focuses on developing treatments for cancer and other diseases using the immune system, with key product candidates like Multikine and LEAPS technology.
2026-07-27 14:11:42
This article from TradingKey reports on CEL-SCI Corp (CVM) revenue breakdown by business segments and regional revenue, and profit contribution. It notes that relevant data for these categories have not yet been disclosed by the company. The page also presents current stock information for CVM.
2026-07-27 10:12:16
This article provides a financial health analysis of CEL-SCI Corp (CVM), stating its current financial score is 5.93, ranking 308 out of 386 in the Biotechnology & Medical Research industry. The company's financial status is described as stable, but its operating efficiency is low. Various financial metrics related to Cash & Equivalents, Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns are mentioned, though specific relevant data have not been disclosed by the company.
2026-07-27 10:11:42
This article details the shareholder structure of CEL-SCI Corp (CVM), listing major shareholders and their proportions, as well as categorizing shareholders by type. It also provides institutional shareholding data over several quarters and recent shareholder activity including changes in holdings for key investors. The data highlights the significant institutional interest in CEL-SCI Corp.
2026-07-27 08:41:52
This article presents the income statement for CEL-SCI Corp (CVM), offering quarterly and annual financial performance data extending back to FY2012Q1. It details key metrics such as total revenue, operating expenses, R&D expenses, depreciation, operating profit, net non-operating interest income/expenses, special income/expenses, other non-operating income/expenses, income before and after tax, net income, and earnings per share. Additionally, it includes an FAQ section explaining how to read the income statement and defining key financial terms.
